CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it will be presenting at three ophthalmology industry conferences in the coming weeks. Eleven will participate in a discussion with experts on dry eye disease and will review Phase 1b/2a clinical data on its lead drug candidate EBI-005 for dry eye disease and preclinical data on EBI-029 for diabetic macular edema.
“Substantial growth in the ophthalmic space and increased interest in new treatment options is evident by the many venues for exchange of medical and scientific information available to physicians, clinicians and drug development experts this spring,” said Abbie C. Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics. “I am pleased that Eleven’s novel approach to treating ocular disease and our pipeline of protein therapeutics are being included at these important industry conferences.”
OIS@ASCRS Annual Meeting, April 24, 2014, Boston, MA:
Dr. Celniker has been invited to participate in a session, along with other industry leaders, on the topic of dry eye disease at the 2014 Ophthalmology Innovation Summit (OIS) @ American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The participants in this session represent a cross section of industry and scientific thought leaders who will discuss the role dry eye technologies and therapies play in ophthalmic practice.
ASCRS Annual Symposium, April 25-29, 2014, Boston, MA:
Michael H. Goldstein, M.D., M.B.A., Eleven Biotherapeutics’ head of Medical Research and co-director of the Cornea, External Disease and Cataract Service group at Tufts University/ New England Eye Center, will present clinical data on Eleven’s lead product candidate EBI-005 for the treatment of dry eye disease at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium.
ARVO 2014 Annual Meeting, May 4-8, 2014, Orlando, FL:
The Association for Research in Vision and Ophthalmology (ARVO) has invited Eleven to give three poster presentations at the ARVO 2014 Annual Meeting. These presentations will elaborate on Eleven’s understanding of cytokine biology to effectively target both front and back of eye diseases. Further, they will include clinical data on Eleven’s lead drug candidate EBI-005 and preclinical data on EBI-029, Eleven’s anti-IL-6 product candidate for the treatment of diabetic macular edema.
Eleven Biotherapeutics’ most advanced product candidate is EBI-005, which was designed, engineered and generated using the Company’s AMP-Rx platform and is being developed as a topical treatment for dry eye disease and allergic conjunctivitis. In 2013, Eleven Biotherapeutics completed a Phase 1b/2a clinical trial of EBI-005 in patients with moderate to severe dry eye disease. The EBI-005 program is based on the role that elevated levels of the inflammatory cytokine interleukin-1, or IL-1, play in the initiation and maintenance of the inflammation and pain associated with dry eye disease and the redness and itching associated with allergic conjunctivitis. EBI-005 is currently being evaluated in a pivotal Phase 3 clinical study in subjects with dry eye disease and a Phase 2 clinical study in subjects with allergic conjunctivitis.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, including expectations regarding timing of initiation of clinical trials, patient enrollment and availability of results, regulatory requirements for initiation of clinical trials and registration of product candidates, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from ongoing clinical trials, whether results of early clinical trials will be indicative of the results of future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals and other factors discussed in the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2014 and other reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.